Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland-Reference-Cited by-同舟云学术

Use of record linkage to evaluate treatment outcomes and trial eligibility in a real‐world metastatic prostate cancer population in Scotland

Published:2020-04-21 Issue:6 Volume:29 Page:653-663
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Baillie Kelly¹^ORCID,Mueller Tanja²^ORCID,Pan Jiafeng³,Laskey Jennifer¹,Bennie Marion²⁴,Crearie Christine¹,Kavanagh Kimberley³,Alvarez‐Madrazo Samantha²,Morrison David⁵,Clarke Julie¹,Keel Aileen⁶,Cameron David⁷,Wu Olivia⁵,Kurdi Amanj²,Jones Robert J.¹⁸

Affiliation:

1. Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde Glasgow UK

2. Strathclyde Institute of Pharmacy and Biomedical Sciences University of Strathclyde Glasgow UK

3. Department of Mathematics and Statistics University of Strathclyde Glasgow UK

4. Public Health Intelligence, NHS National Services Scotland Edinburgh UK

5. Institute of Health and Wellbeing University of Glasgow Glasgow UK

6. Innovative Healthcare Delivery Programme (IHDP) University of Edinburgh Edinburgh UK

7. Cancer Research UK Edinburgh Centre University of Edinburgh Edinburgh UK

8. Institute of Cancer Sciences University of Glasgow Glasgow UK

Funder

Scottish Government

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.4998

Reference31 articles.

1. European Medicines Agency. Annual Report2017.https://www.ema.europa.eu/documents/annual-report/2017-annual-report-european-medicines-agency_en.pdf

2. U.S. Food and Drug Administration. Novel Drug Approvals for 2017. February 02 2018.https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm. Accessed January 11 2019.

3. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines

4. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

5. Abiraterone and Increased Survival in Metastatic Prostate Cancer

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-27

2. Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review;Future Oncology;2023-11

3. Introduction of managed entry agreements in Korea: Problem, policy, and politics;Frontiers in Pharmacology;2023-04-13

4. A fast privacy-preserving patient record linkage of time series data;Scientific Reports;2023-02-25

5. Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018;Future Oncology;2023-02